Story perspectives

Bayer's Shares Soar 8% on Promising Stroke Drug Trial

11/24/2025

Summary

Story summary

Bayer's shares rose over 8% on November 24, 2025, after positive initial clinical trial results for its asundexian drug candidate.
The combination therapy significantly reduced the risk of ischemic stroke in patients with a history of stroke, marking a turnaround after a major setback in 2023.
Bayer CEO Bill Anderson is restructuring the company to address financial debt and ongoing litigation issues.
The Phase III study showed that a daily dose of 50 milligrams of asundexian reduced stroke risk without increasing major bleeding.
Bayer plans to present detailed results at a scientific congress and will engage with health authorities for marketing authorization.

1 of 1

Story summary

Bayer's shares rose over 8% on November 24, 2025, after positive initial clinical trial results for its asundexian drug candidate.
The combination therapy significantly reduced the risk of ischemic stroke in patients with a history of stroke, marking a turnaround after a major setback in 2023.
Bayer CEO Bill Anderson is restructuring the company to address financial debt and ongoing litigation issues.
The Phase III study showed that a daily dose of 50 milligrams of asundexian reduced stroke risk without increasing major bleeding.
Bayer plans to present detailed results at a scientific congress and will engage with health authorities for marketing authorization.